The Marine Compound Isaridin E Ameliorates Lipopolysaccharide-Induced Vascular Endothelial Inflammation via the Downregulation of the TLR4/NF-κB Signaling Pathway
Marine Drugs · 2025
DOI: 10.3390/md23040145 ↗Kurz gefasst
Fachartikel in der Zeitschrift Marine Drugs, 2025. Verfasst von Jing Liu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou 510080, China. Hauptthemen laut MEDLINE: Toll-Like Receptor 4, Anti-Inflammatory Agents, Depsipeptides. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Key R&D Program of Guangdong Province, China, Key-Area Research and Development Program of Guangdong Province, China.
Abstract (Originalsprache)
Isaridin E, a cyclodepsipeptide derived from the marine fungus Beauveria felina (SYSU-MS7908), has been demonstrated to possess multiple biological properties. In this study, we employed both lipopolysaccharide (LPS)-stimulated human umbilical vein endothelial cells (HUVECs) and a LPS-induced murine endotoxemia model to investigate its anti-inflammatory effects. Our results revealed that isaridin E suppressed the expression of pro-inflammatory cytokines and adhesion molecules in a concentration dependent manner, while also reducing monocyte adhesion to endothelial cells. Furthermore, this compound attenuated vascular hyperpermeability and inflammatory cell infiltration in the lungs, as well as preserving the integrity of the aortic and pulmonary tissues. At the molecular level, isaridin E was found to downregulate TLR4 expression, increase IκBα levels, and inhibit the LPS-induced phosphorylation and nuclear translocation of NF-κB p65. In conclusion, our findings indicate that isaridin E exerts robust anti-inflammatory effects in LPS-induced endotoxemia through the suppression of the TLR4/NF-κB signaling axis, positioning it as a promising therapeutic candidate for vascular inflammatory disorders.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou 510080, China.
- Department of Pharmacy, The Second Clinical Medical College, Southern Medical University, Guangzhou 510280, China.
- School of Marine Sciences, Sun Yat-sen University, Guangzhou 510275, China.
- Southern Marine Sciences and Engineering Guangdong Laboratory (Zhuhai), Zhuhai 519000, China.
ORCID-Profile: Lan Liu, Sen-Hua Chen, Yan-Hua Du
Förderung
- National Natural Science Foundation of China
- Key R&D Program of Guangdong Province, China
- Key-Area Research and Development Program of Guangdong Province, China
Zitieren
APA
Liu, J., Zeng, X., Lin, Y. Q., Peng, Y. S., Liu, L., Chen, S. H., & Du, Y. H. (2025). The Marine Compound Isaridin E Ameliorates Lipopolysaccharide-Induced Vascular Endothelial Inflammation via the Downregulation of the TLR4/NF-κB Signaling Pathway. Marine Drugs. https://doi.org/10.3390/md23040145
Vancouver
Liu J, Zeng X, Lin YQ, Peng YS, Liu L, Chen SH, et al. The Marine Compound Isaridin E Ameliorates Lipopolysaccharide-Induced Vascular Endothelial Inflammation via the Downregulation of the TLR4/NF-κB Signaling Pathway. Marine Drugs. 2025. doi:10.3390/md23040145
BibTeX
@article{Liu2025,
author = {Liu, Jing and Zeng, Xin and Lin, Yu-Quan and Peng, Yu-Sheng and Liu, Lan and Chen, Sen-Hua and Du, Yan-Hua},
title = {The Marine Compound Isaridin E Ameliorates Lipopolysaccharide-Induced Vascular Endothelial Inflammation via the Downregulation of the TLR4/NF-κB Signaling Pathway},
journal = {Marine Drugs},
year = {2025},
doi = {10.3390/md23040145}
}
EUVIMED